The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase

Yu Ri Kim, Soo Jeong Kim, June Won Cheong, Deok Hwan Yang, Hyewon Lee, Hyeon Seok Eom, Yong Oh Sung, Hyo Jung Kim, Hye Jin Kang, Won Sik Lee, Yong Park, Woo Ick Yang, Yoo Hong Min, Jin Seok Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The non-germinal center B cell (non-GCB) subtype of diffuse large B cell lymphoma (DLBCL) is more related to poor prognosis than the GCB subtype. To investigate the role of molecular classification according to upfront autologous hematopoietic stem cell transplantation (ASCT), we retrospectively evaluated 219 newly diagnosed high-risk DLBCL patients. Eighty-one patients were in the ASCT group, and 138 patients were in the non-ASCT group. The ASCT group yielded significantly better overall survival (OS) and progression-free survival (PFS) than the non-ASCT group (p = 0.038 and p = 0.007), and patients with the non-GCB subtype were more related to inferior PFS than those with the GCB subtype (p = 0.020). After performing age-matching by using propensity scores, upfront ASCT continued to show better OS and PFS than non-ASCT (p = 0.046 and p = 0.026). In the non-ASCT group, the non-GCB subtype showed worse OS and PFS than the GCB subtype (p = 0.039 and p = 0.007). Patients who achieved complete response showed differences in OS and PFS according to molecular subtype (p = 0.007 and p = 0.002). In the ASCT group, there were no significant differences in OS and PFS according to molecular classification (p = 0.277 and p = 0.892). In conclusion, non-GCB subtype DLBCL patients showed poor OS and PFS in the non-ASCT group while they did not show clinical significance in the ASCT group. This suggests the possibility that upfront ASCT may improve the poor prognosis of non-GCB subtype in high-risk DLBCL.

Original languageEnglish
Pages (from-to)1491-1501
Number of pages11
JournalAnnals of Hematology
Volume95
Issue number9
DOIs
Publication statusPublished - 2016 Sep 1

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
L-Lactate Dehydrogenase
Disease-Free Survival
Serum
B-Lymphocytes
Survival
Propensity Score

Keywords

  • Autologous hematopoietic stem cell transplantation
  • Diffuse large B cell lymphoma
  • Germinal center B cell
  • Non-germinal center B cell
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. / Kim, Yu Ri; Kim, Soo Jeong; Cheong, June Won; Yang, Deok Hwan; Lee, Hyewon; Eom, Hyeon Seok; Sung, Yong Oh; Kim, Hyo Jung; Kang, Hye Jin; Lee, Won Sik; Park, Yong; Yang, Woo Ick; Min, Yoo Hong; Kim, Jin Seok.

In: Annals of Hematology, Vol. 95, No. 9, 01.09.2016, p. 1491-1501.

Research output: Contribution to journalArticle

Kim, Yu Ri ; Kim, Soo Jeong ; Cheong, June Won ; Yang, Deok Hwan ; Lee, Hyewon ; Eom, Hyeon Seok ; Sung, Yong Oh ; Kim, Hyo Jung ; Kang, Hye Jin ; Lee, Won Sik ; Park, Yong ; Yang, Woo Ick ; Min, Yoo Hong ; Kim, Jin Seok. / The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. In: Annals of Hematology. 2016 ; Vol. 95, No. 9. pp. 1491-1501.
@article{32765687a0184a96804f906ccdc6b6b4,
title = "The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase",
abstract = "The non-germinal center B cell (non-GCB) subtype of diffuse large B cell lymphoma (DLBCL) is more related to poor prognosis than the GCB subtype. To investigate the role of molecular classification according to upfront autologous hematopoietic stem cell transplantation (ASCT), we retrospectively evaluated 219 newly diagnosed high-risk DLBCL patients. Eighty-one patients were in the ASCT group, and 138 patients were in the non-ASCT group. The ASCT group yielded significantly better overall survival (OS) and progression-free survival (PFS) than the non-ASCT group (p = 0.038 and p = 0.007), and patients with the non-GCB subtype were more related to inferior PFS than those with the GCB subtype (p = 0.020). After performing age-matching by using propensity scores, upfront ASCT continued to show better OS and PFS than non-ASCT (p = 0.046 and p = 0.026). In the non-ASCT group, the non-GCB subtype showed worse OS and PFS than the GCB subtype (p = 0.039 and p = 0.007). Patients who achieved complete response showed differences in OS and PFS according to molecular subtype (p = 0.007 and p = 0.002). In the ASCT group, there were no significant differences in OS and PFS according to molecular classification (p = 0.277 and p = 0.892). In conclusion, non-GCB subtype DLBCL patients showed poor OS and PFS in the non-ASCT group while they did not show clinical significance in the ASCT group. This suggests the possibility that upfront ASCT may improve the poor prognosis of non-GCB subtype in high-risk DLBCL.",
keywords = "Autologous hematopoietic stem cell transplantation, Diffuse large B cell lymphoma, Germinal center B cell, Non-germinal center B cell, Rituximab",
author = "Kim, {Yu Ri} and Kim, {Soo Jeong} and Cheong, {June Won} and Yang, {Deok Hwan} and Hyewon Lee and Eom, {Hyeon Seok} and Sung, {Yong Oh} and Kim, {Hyo Jung} and Kang, {Hye Jin} and Lee, {Won Sik} and Yong Park and Yang, {Woo Ick} and Min, {Yoo Hong} and Kim, {Jin Seok}",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s00277-016-2729-4",
language = "English",
volume = "95",
pages = "1491--1501",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase

AU - Kim, Yu Ri

AU - Kim, Soo Jeong

AU - Cheong, June Won

AU - Yang, Deok Hwan

AU - Lee, Hyewon

AU - Eom, Hyeon Seok

AU - Sung, Yong Oh

AU - Kim, Hyo Jung

AU - Kang, Hye Jin

AU - Lee, Won Sik

AU - Park, Yong

AU - Yang, Woo Ick

AU - Min, Yoo Hong

AU - Kim, Jin Seok

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The non-germinal center B cell (non-GCB) subtype of diffuse large B cell lymphoma (DLBCL) is more related to poor prognosis than the GCB subtype. To investigate the role of molecular classification according to upfront autologous hematopoietic stem cell transplantation (ASCT), we retrospectively evaluated 219 newly diagnosed high-risk DLBCL patients. Eighty-one patients were in the ASCT group, and 138 patients were in the non-ASCT group. The ASCT group yielded significantly better overall survival (OS) and progression-free survival (PFS) than the non-ASCT group (p = 0.038 and p = 0.007), and patients with the non-GCB subtype were more related to inferior PFS than those with the GCB subtype (p = 0.020). After performing age-matching by using propensity scores, upfront ASCT continued to show better OS and PFS than non-ASCT (p = 0.046 and p = 0.026). In the non-ASCT group, the non-GCB subtype showed worse OS and PFS than the GCB subtype (p = 0.039 and p = 0.007). Patients who achieved complete response showed differences in OS and PFS according to molecular subtype (p = 0.007 and p = 0.002). In the ASCT group, there were no significant differences in OS and PFS according to molecular classification (p = 0.277 and p = 0.892). In conclusion, non-GCB subtype DLBCL patients showed poor OS and PFS in the non-ASCT group while they did not show clinical significance in the ASCT group. This suggests the possibility that upfront ASCT may improve the poor prognosis of non-GCB subtype in high-risk DLBCL.

AB - The non-germinal center B cell (non-GCB) subtype of diffuse large B cell lymphoma (DLBCL) is more related to poor prognosis than the GCB subtype. To investigate the role of molecular classification according to upfront autologous hematopoietic stem cell transplantation (ASCT), we retrospectively evaluated 219 newly diagnosed high-risk DLBCL patients. Eighty-one patients were in the ASCT group, and 138 patients were in the non-ASCT group. The ASCT group yielded significantly better overall survival (OS) and progression-free survival (PFS) than the non-ASCT group (p = 0.038 and p = 0.007), and patients with the non-GCB subtype were more related to inferior PFS than those with the GCB subtype (p = 0.020). After performing age-matching by using propensity scores, upfront ASCT continued to show better OS and PFS than non-ASCT (p = 0.046 and p = 0.026). In the non-ASCT group, the non-GCB subtype showed worse OS and PFS than the GCB subtype (p = 0.039 and p = 0.007). Patients who achieved complete response showed differences in OS and PFS according to molecular subtype (p = 0.007 and p = 0.002). In the ASCT group, there were no significant differences in OS and PFS according to molecular classification (p = 0.277 and p = 0.892). In conclusion, non-GCB subtype DLBCL patients showed poor OS and PFS in the non-ASCT group while they did not show clinical significance in the ASCT group. This suggests the possibility that upfront ASCT may improve the poor prognosis of non-GCB subtype in high-risk DLBCL.

KW - Autologous hematopoietic stem cell transplantation

KW - Diffuse large B cell lymphoma

KW - Germinal center B cell

KW - Non-germinal center B cell

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84975247303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975247303&partnerID=8YFLogxK

U2 - 10.1007/s00277-016-2729-4

DO - 10.1007/s00277-016-2729-4

M3 - Article

C2 - 27324387

AN - SCOPUS:84975247303

VL - 95

SP - 1491

EP - 1501

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 9

ER -